Mixtard 30 Innolet (Insulin Human)

Insulin human, the active ingredient in Mixtard 30 Innolet, is an insulin presented as a prefilled pen injection for subcutaneous use. It treats diabetes mellitus in both type 1 and type 2 patients.

GNH USA supplies Mixtard 30 Innolet as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mixtard 30 Innolet is an insulin preparation used to manage blood glucose in diabetes mellitus. - Type 1 diabetes mellitus: provides basal and prandial insulin coverage to achieve glycaemic control. - Type 2 diabetes mellitus: used when oral agents are insufficient to reach target glucose levels. - Insulin‑requiring diabetes: supplies exogenous insulin to replace deficient endogenous production.

Common Side Effects: - Hypoglycaemia: low blood sugar episodes, especially if dose exceeds need. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increased caloric storage due to improved glucose utilization. - Lipodystrophy: localized fat tissue changes at repeated injection sites. - Edema: mild fluid retention, often peripheral.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypoglycaemia with seizures or loss of consciousness. - Development of insulin antibodies that may alter drug efficacy. - Lipohypertrophy: painful thickened tissue that can affect insulin absorption. - Hypokalemia: low potassium levels secondary to rapid glucose shift into cells.

Mixtard 30 Innolet requires careful clinical monitoring and patient education. - Dose adjustment: tailor dose to individual blood glucose monitoring results. - Renal impairment: may need lower doses due to reduced clearance. - Hepatic impairment: monitor glucose closely as metabolism may be altered. - Pregnancy: use only if benefits outweigh potential risks. - Hypoglycaemia risk: educate patients on recognizing and treating low blood sugar. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mixtard 30 Innolet can interact with several drug classes. Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycaemia symptoms. - MAO inhibitors: can potentiate insulin’s glucose‑lowering effect. - Concurrent insulin products: increase risk of overdose. Moderate Interactions (Monitor Closely): - Sulfonylureas or other oral hypoglycaemics: additive glucose‑lowering effect. - Thiazide diuretics: may raise blood glucose levels. - Corticosteroids: may increase insulin requirements.